Vertex Pharma (VRTX) Tops Q1 EPS by 2c; Reaffirms
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $451.63 --0%
Revenue Growth %: +8.4%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +8.4%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $3.05, $0.02 better than the analyst estimate of $3.03. Revenue for the quarter came in at $2.37 billion versus the consensus estimate of $2.34 billion.
GUIDANCE:
Vertex Pharma reaffirms FY2023 revenue of $9.55-9.7 billion, versus the consensus of $9.7 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
- Syensqo SA (SYENS:BB) PT Raised to EUR74 at Deutsche Bank
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
